Search
Solcitinib
go.drugbank.com/drugs/DB19856InvestigationalSolcitinib has a monoisotopic molecular weight of 389.19 Da. … Solcitinib is under investigation in clinical trial NCT01777256 (An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184).
Amrinone
go.drugbank.com/drugs/DB01427ApprovedWithdrawnAmrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnWhile it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated … Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesChlorothiazide
go.drugbank.com/drugs/DB00880ApprovedInvestigationalVet approvedA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Quinethazone
go.drugbank.com/drugs/DB01325ApprovedQuinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
DG051
go.drugbank.com/drugs/DB05177ExperimentalDG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
Cerulenin
go.drugbank.com/drugs/DB01034ExperimentalCerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols.
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalINCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. It represents a potentially important new class of targeted breast cancer therapy. ...
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measure...